Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease
08 janv. 2025 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
19 déc. 2024 08h00 HE
|
Alumis Inc.
In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.
Harness Therapeutics appoints Leading World Experts in Neurodegenerative Diseases to its Scientific Advisory Board (SAB)
30 mai 2024 07h00 HE
|
Harness Therapeutics
Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme HRN001 Cambridge, UK, May 30, 2024:...
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
08 mai 2024 09h00 HE
|
Therini Bio, Inc.
THN391, a mAb designed to block neuroinflammation triggered by fibrin, demonstrated effectiveness in protecting against vascular and neuronal degeneration
Neurodegenerative Disease Market Size To Reach USD 96.4 Billion By 2032 | DataHorizzon Research
12 févr. 2024 07h10 HE
|
DataHorizzon Research
Fort Collins, Colorado, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Neurodegenerative Disease Market size was valued at USD 51.2 Billion in 2023 and is anticipated to reach USD 96.4 Billion by 2032 at a...
MitoRx Therapeutics Announces Close of Seed Extension Financing Round to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases
13 déc. 2023 03h00 HE
|
MitoRx Therapeutics
OXFORD, United Kingdom, Dec. 13, 2023 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the...
Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases
28 nov. 2023 04h00 HE
|
Harness Therapeutics
Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesisRefined focus on neurodegenerative...
Vyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of Stockholders
11 oct. 2023 11h45 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the...
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
11 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes
IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders
12 juil. 2023 03h00 HE
|
IRBM
Multi-year drug discovery collaboration to identify small molecule cGAS inhibitors for treating neurodegenerative diseases including Alzheimer’s ROME, July 12, 2023 (GLOBE NEWSWIRE) -- IRBM,...